In this review, we discuss BCR::ABL1-dependent and BCR::ABL1-independent mechanisms of TKI resistance in CML, highlighting combination-treatment strategies for overcoming resistance in a situation where resistance is driven by a BCR::ABL1-independent mechanism. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.